Clinical aspects and therapy of gastrointestinal MALT lymphoma

被引：38
作者：
Thieblemont, Catherine [1 ]
Zucca, Emanuele [2 ]
机构：
[1] Univ Diderot Sorbonne Paris Cite, Hop St Louis, AP HP, Hematooncol, Paris, France
[2] Osped San Giovanni Bellinzona, Oncol Inst Southern Switzerland IOSI, Lymphoma Unit, Div Res, CH-6500 Bellinzona, Switzerland
来源：
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2017年 / 30卷 / 1-2期
关键词：
Gastro-intestinal MALT lymphoma; Antibiotics; Radiotherapy; R-chlorambucil; R-bendamustine; B-CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; HELICOBACTER-PYLORI ERADICATION; SMALL-INTESTINAL DISEASE; TISSUE LYMPHOMA; NUCLEAR EXPRESSION; T(11/18)(Q21; Q21); RITUXIMAB; STAGE; BCL10;
D O I：
10.1016/j.beha.2017.01.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Extranodal marginal zone B-cell lymphomas of the mucosa associated lymphoid tissue (MALT) arise from lymphoid populations that are induced by chronic inflammation in extranodal sites. Among the MALT lymphomas, gastrointestinal (GIT) MALT, lymphoma is the most frequent compared to non-GIT MALT lymphoma arising from other sites. Gastric MALT lymphoma has been the first to be described with the evidence of an etiopathogenetic link provided by the association between Helicobacter pylon-positive gastritis and gastric MALT lymphoma. Indeed, successful eradication of this micro-organism with antibiotics can be followed by a lymphoma regression in most cases. When there is no association with Helicobacter pylori, there is no clear therapeutic consensus. Both radiotherapy and systemic treatments with chemotherapy and anti-CD20 antibodies are efficacious and thus the experience of individual centers and each patient's preferences in terms of adverse effects are important parameters in the decision process. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码：109 / 117
页数：9
相关论文
共 74 条
[1]  
Akbulut H, 1997, CANCER, V80, P8, DOI 10.1002/(SICI)1097-0142(19970701)80:1<8::AID-CNCR2>3.0.CO
[2]  
2-T
[3]   Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms [J].
Al-Saleem, T ;
Al-Mondhiry, H .
BLOOD, 2005, 105 (06) :2274-2280
[4]   Indolent B-Cell Lymphomas Associated with HCV Infection: Clinical and Virological Features and Role of Antiviral Therapy [J].
Arcaini, Luca ;
Merli, Michele ;
Volpetti, Stefano ;
Rattotti, Sara ;
Gotti, Manuel ;
Zaja, Francesco .
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,
[5]   Selective expansion of marginal zone B cells in Eμ-API2-MALT1 mice is linked to enhanced IκB kinase γ polyubiquitination [J].
Baens, Mathijs ;
Fevery, Sabine ;
Sagaert, Xavier ;
Noels, Heidi ;
Hagens, Sofie ;
Broeckx, Vicky ;
Billiau, An D. ;
De Wolf-Peeters, Christiane ;
Marynen, Peter .
CANCER RESEARCH, 2006, 66 (10) :5270-5277
[6]  
BENAYED F, 1989, CANCER-AM CANCER SOC, V63, P1251, DOI 10.1002/1097-0142(19890401)63:7<1251::AID-CNCR2820630704>3.0.CO
[7]  
2-H
[8]   A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas [J].
Brown, Jennifer R. ;
Friedberg, Jonathan W. ;
Feng, Yang ;
Scofield, Sarah ;
Phillips, Kimberly ;
Dal Cin, Paola ;
Joyce, Robin ;
Takvorian, Ronald W. ;
Fisher, David C. ;
Fisher, Richard I. ;
Liesveld, Jane ;
Marquis, Diana ;
Neuberg, Donna ;
Freedman, Arnold S. .
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 (06) :741-748
[9]   Gastric MALT lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide study [J].
Capelle, L. G. ;
de Vries, A. C. ;
Looman, C. W. N. ;
Casparie, M. K. ;
Boot, H. ;
Meijer, G. A. ;
Kuipers, E. J. .
EUROPEAN JOURNAL OF CANCER, 2008, 44 (16) :2470-2476
[10]   Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma [J].
Carrillo-Cruz, Estrella ;
Marin-Oyaga, Victor A. ;
de la Cruz Vicente, Fatima ;
Borrego-Dorado, Isabel ;
Ruiz Mercado, Marta ;
Acevedo Banez, Irene ;
Sole Rodriguez, Maria ;
Fernandez Lopez, Rosa ;
Perez Vega, Herminia ;
Calderon-Cabrera, Cristina ;
Espigado Tocino, Ildefonso ;
Perez-Simon, Jose A. ;
Vazquez-Albertino, Ricardo .
HEMATOLOGICAL ONCOLOGY, 2015, 33 (04) :151-158
12345678